New study tests aggressive BP management to protect heart and kidneys in cancer patients

NCT ID NCT04467021

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase II trial tests whether intensive blood pressure management (targeting systolic BP below 120 mmHg) is better than standard care (below 140 mmHg) for patients with advanced kidney or thyroid cancer starting anti-angiogenic TKI therapy. The study enrolls 61 participants and measures blood pressure differences over 6 months. The goal is to find the safest way to manage BP during cancer treatment to reduce cardiovascular and kidney risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
intensive blood pressure management (target systolic BP <120 mmHg)
What this could lead to
If successful, this could show that aggressive blood pressure control reduces heart and kidney complications in cancer patients on certain therapies.
What could go wrong
This is a small, early-phase study (61 participants) focused on feasibility, not hard outcomes. Results may not apply broadly, and intensive BP lowering carries risks like dizziness or fainting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Aurora Bay Area Medical Group-Marinette

    Marinette, Wisconsin, 54143, United States

  • Aurora BayCare Medical Center

    Green Bay, Wisconsin, 54311, United States

  • Aurora Cancer Care-Grafton

    Grafton, Wisconsin, 53024, United States

  • Aurora Cancer Care-Kenosha South

    Kenosha, Wisconsin, 53142, United States

  • Aurora Cancer Care-Milwaukee

    Milwaukee, Wisconsin, 53209, United States

  • Aurora Cancer Care-Milwaukee West

    Wauwatosa, Wisconsin, 53226, United States

  • Aurora Cancer Care-Racine

    Racine, Wisconsin, 53406, United States

  • Aurora Cancer Care-Southern Lakes VLCC

    Burlington, Wisconsin, 53105, United States

  • Aurora Health Care Germantown Health Center

    Germantown, Wisconsin, 53022, United States

  • Aurora Medical Center in Summit

    Summit, Wisconsin, 53066, United States

  • Aurora Saint Luke's Medical Center

    Milwaukee, Wisconsin, 53215, United States

  • Aurora Saint Luke's South Shore

    Cudahy, Wisconsin, 53110, United States

  • Aurora Sinai Medical Center

    Milwaukee, Wisconsin, 53233, United States

  • Aurora West Allis Medical Center

    West Allis, Wisconsin, 53227, United States

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York, 10467, United States

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York, 10461, United States

  • Montefiore Medical Center-Weiler Hospital

    The Bronx, New York, 10461, United States

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri, 63141, United States

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas, 75390, United States

  • University of Pennsylvania/Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania, 15232, United States

  • Vince Lombardi Cancer Clinic - Oshkosh

    Oshkosh, Wisconsin, 54904, United States

  • Vince Lombardi Cancer Clinic-Sheboygan

    Sheboygan, Wisconsin, 53081, United States

  • Vince Lombardi Cancer Clinic-Two Rivers

    Two Rivers, Wisconsin, 54241, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.